The introduction of nicotinamide to be a nicotine substitute in e-cigarette and smokeless solutions represents a significant regulatory obstacle for that FDA. Nicotinamide does not have nicotinic receptor agonist activity and is understood to work as a sedative at large dosages6. The promises created by Nicotine River, ECBlend, along with other dis